AMLX
Amylyx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$34.10
+0.41%Aug 18, 2026, 20:01 UTC
Amylyx Pharmaceuticals announced the commencement of an underwritten public offering of $350.0 million of its common stock, with an option for underwriters to purchase up to an additional $52.5 million of shares.
Aug 18, 2026, 17:08 UTC
Amylyx Pharmaceuticals announced positive phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia, meeting its primary endpoint with a 55% reduction in severe hypoglycemic events.
Aug 18, 2026, 11:01 UTC
Amylyx Pharmaceuticals announced positive Phase 3 trial results for its experimental drug treating post-bariatric hypoglycemia, showing a 55% reduction in serious low blood sugar events versus placebo, paving the way for potential approval.
Aug 6, 2026, 15:06 UTC
Amylyx Pharmaceuticals announced that its pivotal Phase III LUCIDITY trial of avexitide in post-bariatric hypoglycemia has completed final patient visits, with top-line data expected in late August or early September.
Aug 6, 2026, 11:00 UTC
Amylyx Pharmaceuticals reported its financial results for the second quarter of 2026.
Source: